Seven new advanced therapy medicinal products (ATMPs) could be approved for pan-EU approval this year, based on data from the Pink Sheet’s EU regulatory filings tracker, including Roche/Sarepta Therapeutics’ Duchenne gene therapy delandistrogene moxeparvovec, known as Elevidys in the US and several other nations where it is already approved.
During 2024, five companies filed EU marketing authorization applications (MAAs) for ATMPs, up from four in 2023, one in 2022 and three in 2021. The number of filings in 2024 is the highest since 2020, when nine ATMPs were filed
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?